Filing Flows › Pulse Biosciences (PLSE) › Q3 2026
Pulse Biosciences (PLSE) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 5, 2026
Pulse Biosciences (PLSE) reported revenue of $395K for the third quarter 2026 (Q3 2026), +359% from a year earlier and -9% from the quarter before.
Pulse Biosciences, Q3 2026: revenue $395K (+359% year over year), net loss $23.1M, operating cash flow −$15.3M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $395K | -9% | +359% |
| Operating profit | −$24.3M | — | — |
| Net earnings | −$23.1M | — | — |
| Operating cash flow | −$15.3M | — | — |
What changed
Revenue was $395K in Q3 2026, up 359% year over year and down 9% from the previous quarter.
Operating costs exceeded revenue by $24.3M, an operating margin of -6149.9%. Total costs grew 21% against revenue growth of 359%. The fastest-growing cost line was Research & development (+48%). The quarter ended with a net loss of $23.1M, narrower than the previous quarter's $24.7M loss.
Operating cash flow was −$15.3M. Non-cash charges added back $261K of depreciation and amortization and $5.3M of share-based compensation. Working capital and other items added $2.2M. Capital expenditures of $142K exceeded it, leaving free cash flow of −$15.4M.
Questions
What was Pulse Biosciences' revenue in the third quarter 2026?
Pulse Biosciences (PLSE) reported revenue of $395K for the third quarter 2026 (Q3 2026), +359% from a year earlier and -9% from the quarter before.
Source: Pulse Biosciences 10-Q on SEC EDGAR.